MX2021009679A - Minimizacion de aglomeracion, aireacion y conservacion del revestimiento de composiciones farmaceuticas que comprenden ibuprofeno. - Google Patents
Minimizacion de aglomeracion, aireacion y conservacion del revestimiento de composiciones farmaceuticas que comprenden ibuprofeno.Info
- Publication number
- MX2021009679A MX2021009679A MX2021009679A MX2021009679A MX2021009679A MX 2021009679 A MX2021009679 A MX 2021009679A MX 2021009679 A MX2021009679 A MX 2021009679A MX 2021009679 A MX2021009679 A MX 2021009679A MX 2021009679 A MX2021009679 A MX 2021009679A
- Authority
- MX
- Mexico
- Prior art keywords
- ibuprofen
- coating
- pharmaceutical compositions
- aeration
- preserving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan composiciones y métodos farmacéuticos para preparar composiciones farmacéuticas que comprenden Ibuprofeno usando métodos de mezcla sin solvente. El exceso de material de revestimiento que no está unido al Ibuprofeno revestido puede ser retirado mediante un proceso de tamizado. Los índices de revestimiento y dosificación también pueden ser optimizados para minimizar la cantidad de exceso de material de revestimiento no unido. Adicionalmente, las composiciones pueden formularse para preservar el revestimiento funcional del Ibuprofeno revestido y para minimizar la aireación del Ibuprofeno cuando se mezcla en suspensión.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962809287P | 2019-02-22 | 2019-02-22 | |
US201962809293P | 2019-02-22 | 2019-02-22 | |
US201962809307P | 2019-02-22 | 2019-02-22 | |
PCT/GB2020/050420 WO2020169989A1 (en) | 2019-02-22 | 2020-02-21 | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009679A true MX2021009679A (es) | 2021-09-10 |
Family
ID=69740393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009679A MX2021009679A (es) | 2019-02-22 | 2020-02-21 | Minimizacion de aglomeracion, aireacion y conservacion del revestimiento de composiciones farmaceuticas que comprenden ibuprofeno. |
Country Status (17)
Country | Link |
---|---|
US (3) | US11166919B2 (es) |
EP (2) | EP4282409A3 (es) |
JP (1) | JP2022521318A (es) |
KR (1) | KR20210129649A (es) |
CN (1) | CN113490486A (es) |
AU (1) | AU2020223894A1 (es) |
BR (1) | BR112021016421A2 (es) |
CA (1) | CA3129395A1 (es) |
ES (1) | ES2966816T3 (es) |
GB (2) | GB2597577B (es) |
HU (1) | HUE064472T2 (es) |
IL (1) | IL285653A (es) |
MX (1) | MX2021009679A (es) |
PL (1) | PL3927312T3 (es) |
SG (1) | SG11202108690YA (es) |
TW (1) | TW202045153A (es) |
WO (1) | WO2020169989A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202108690YA (en) | 2019-02-22 | 2021-09-29 | Catalent Uk Swindon Zydis Ltd | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen |
EP3927313A1 (en) | 2019-02-22 | 2021-12-29 | Catalent U.K. Swindon Zydis Limited | Preserving functionally-coated api particles produced by solventless mixing processes in aqueous suspension |
TW202045142A (zh) | 2019-02-22 | 2020-12-16 | 英商康泰倫特英國斯文敦載迪斯有限公司 | 將儲存期間藥物顆粒塗覆材料的黏聚最小化以穩定化醫藥產品的崩解時間 |
IL300129A (en) * | 2020-07-31 | 2023-03-01 | Catalent Uk Swindon Zydis Ltd | Pharmaceutical preparations containing a coated API |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB211423A (en) | 1923-10-06 | 1924-02-21 | Leopold Seeger | Improved means for locking nuts |
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
CA1097233A (en) | 1977-07-20 | 1981-03-10 | George K. E. Gregory | Packages |
IE53696B1 (en) | 1981-12-02 | 1989-01-18 | Wyeth John & Brother Ltd | Solid shaped articles |
IT1183574B (it) | 1985-05-08 | 1987-10-22 | Eurand Spa | Metodo per ottenere una sospensione estemporanea omogenea di microcapsule |
US5558880A (en) | 1989-12-22 | 1996-09-24 | Janssen Pharmaceutica Inc. | Pharmaceutical and other dosage forms |
ATE245023T1 (de) | 1991-05-28 | 2003-08-15 | Mcneil Ppc Inc | Kaubare zusammensetzung zur arzneimittelfreisetzung |
DE4119116C2 (de) | 1991-06-10 | 1997-08-07 | Boehme Chem Fab Kg | Biologisch leicht eliminierbare Entschäumer für wäßrige Systeme |
CA2128821A1 (en) * | 1993-07-27 | 1995-01-28 | Dilip J. Gole | Freeze-dried pharmaceutical dosage form and process for separation thereof |
CA2134611C (en) | 1994-10-28 | 2002-12-24 | Richard John Yarwood | Process for preparing solid pharmaceutical dosage forms |
US6214386B1 (en) | 1995-11-22 | 2001-04-10 | Recordati, S.A. | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions |
US5976577A (en) | 1997-07-11 | 1999-11-02 | Rp Scherer Corporation | Process for preparing fast dispersing solid oral dosage form |
GB9814534D0 (en) | 1998-07-03 | 1998-09-02 | Courtaulds Coatings Holdings | Powder coating compositions |
FR2785539B1 (fr) | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Particules enrobees d'ibuprofene cristallin granule |
GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
JP2002012557A (ja) | 2000-06-28 | 2002-01-15 | Lion Corp | 内服薬組成物 |
ES2396598T3 (es) | 2000-08-25 | 2013-02-22 | Senju Pharmaceutical Co., Ltd. | Preparaciones en forma de suspensiones acuosas |
IN192750B (es) | 2000-12-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
JP2003055197A (ja) | 2001-06-07 | 2003-02-26 | Tanabe Seiyaku Co Ltd | 機能性粒子含有口腔内速崩壊性製剤 |
CA2449731A1 (en) * | 2001-06-07 | 2002-12-19 | Tanabe Seiyaku Co., Ltd. | Functional grain-containing preparations quickly disintegrated in the oral cavity |
US20030185096A1 (en) | 2002-11-26 | 2003-10-02 | Hollstein Thomas E. | Apparatus and methods for dispensing minute amounts of liquid |
FR2850275B1 (fr) | 2003-01-24 | 2005-04-08 | Scherer Technologies Inc R P | Capsules molles a macher contenant une substance active a gout masque |
US20040170686A1 (en) | 2003-01-31 | 2004-09-02 | Fredrickson Jennifer K. | Suspension vehicle for coated drug particles |
US20040265373A1 (en) * | 2003-06-27 | 2004-12-30 | David Wynn | Soft tablet containing high molecular weight cellulosics |
EP1621186A1 (en) | 2004-07-29 | 2006-02-01 | Cephalon France | Modafinil oral lyophilizate |
KR101379297B1 (ko) * | 2004-10-28 | 2014-04-10 | 팬택 아게 | 고 다공성, 속해성 고형 투여 형태 및 분말 제조 및동결건조 단계를 포함하는 그의 제조 방법 |
US20080096979A1 (en) | 2004-11-08 | 2008-04-24 | Rubicon Research Pvt. Ltd. | Aqueous Pharmaceutical Coating |
WO2007074472A2 (en) | 2005-12-27 | 2007-07-05 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide |
US20070148099A1 (en) | 2005-12-27 | 2007-06-28 | Burke Susan E | Use of aroma compounds as defoaming agents for ophthalmic solutions with high concentrations of surfactants |
CA2634232C (en) | 2005-12-28 | 2013-08-20 | Takeda Pharmaceutical Company Limited | Method of producing solid preparation disintegrating in the oral cavity |
US20070292508A1 (en) | 2006-06-05 | 2007-12-20 | Balchem Corporation | Orally disintegrating dosage forms |
CN101516331A (zh) * | 2006-09-20 | 2009-08-26 | 莫诺索尔克斯有限公司 | 含有抗泡沫调味剂的可食用水溶性膜 |
US20080113021A1 (en) | 2006-10-25 | 2008-05-15 | Robert Shen | Ibuprofen composition |
US9833510B2 (en) | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
US20090226522A1 (en) | 2008-02-28 | 2009-09-10 | Howes Simon A M | Process to minimize polymorphism |
PT2391345E (pt) | 2009-01-28 | 2014-12-03 | Novartis Ag | Formulações galénicas compreendendo aliscireno |
CA2818891C (en) | 2009-11-27 | 2016-01-19 | Nuvo Research Inc. | Topical ibuprofen formulations |
US10548839B2 (en) | 2010-03-16 | 2020-02-04 | Wei Tian | Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form |
CN102579390A (zh) * | 2011-08-03 | 2012-07-18 | 天津市嵩锐医药科技有限公司 | 布洛芬定时释药三层片药物组合物及其制备方法 |
EP2741750A1 (en) | 2011-08-12 | 2014-06-18 | Dhanuka Laboratories Ltd. | Pharmaceutical composition comprising cefuroxime |
RU2476206C1 (ru) * | 2011-11-22 | 2013-02-27 | Виктор Львович Лимонов | Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты) |
WO2013183062A2 (en) * | 2012-06-05 | 2013-12-12 | Rubicon Research Private Limited | Palatable formulations of ibuprofen |
US9107851B2 (en) | 2012-10-15 | 2015-08-18 | New Jersey Institute Of Technology | Solventless mixing process for coating pharmaceutical ingredients |
ES2761407T3 (es) | 2013-03-15 | 2020-05-19 | Aprecia Pharmaceuticals LLC | Forma de dosificación rápidamente dispersable de topiramato |
WO2017080566A1 (en) * | 2015-11-09 | 2017-05-18 | Rontis Hellas S.A. | Stable analgesic pharmaceutical composition and process for the preparation thereof |
TW202045139A (zh) | 2019-02-22 | 2020-12-16 | 英商康泰倫特英國斯文敦載迪斯有限公司 | 最小化線上混合期間之懸浮液之通氣 |
TW202045142A (zh) | 2019-02-22 | 2020-12-16 | 英商康泰倫特英國斯文敦載迪斯有限公司 | 將儲存期間藥物顆粒塗覆材料的黏聚最小化以穩定化醫藥產品的崩解時間 |
EP3927313A1 (en) | 2019-02-22 | 2021-12-29 | Catalent U.K. Swindon Zydis Limited | Preserving functionally-coated api particles produced by solventless mixing processes in aqueous suspension |
SG11202108690YA (en) | 2019-02-22 | 2021-09-29 | Catalent Uk Swindon Zydis Ltd | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen |
-
2020
- 2020-02-21 SG SG11202108690YA patent/SG11202108690YA/en unknown
- 2020-02-21 WO PCT/GB2020/050420 patent/WO2020169989A1/en unknown
- 2020-02-21 TW TW109105773A patent/TW202045153A/zh unknown
- 2020-02-21 CN CN202080015572.0A patent/CN113490486A/zh active Pending
- 2020-02-21 PL PL20708583.8T patent/PL3927312T3/pl unknown
- 2020-02-21 ES ES20708583T patent/ES2966816T3/es active Active
- 2020-02-21 GB GB2107172.5A patent/GB2597577B/en active Active
- 2020-02-21 KR KR1020217025485A patent/KR20210129649A/ko unknown
- 2020-02-21 HU HUE20708583A patent/HUE064472T2/hu unknown
- 2020-02-21 GB GB2002484.0A patent/GB2585414B/en active Active
- 2020-02-21 BR BR112021016421-9A patent/BR112021016421A2/pt unknown
- 2020-02-21 US US16/798,130 patent/US11166919B2/en active Active
- 2020-02-21 EP EP23189317.3A patent/EP4282409A3/en active Pending
- 2020-02-21 CA CA3129395A patent/CA3129395A1/en active Pending
- 2020-02-21 MX MX2021009679A patent/MX2021009679A/es unknown
- 2020-02-21 AU AU2020223894A patent/AU2020223894A1/en active Pending
- 2020-02-21 JP JP2021549374A patent/JP2022521318A/ja active Pending
- 2020-02-21 EP EP20708583.8A patent/EP3927312B1/en active Active
- 2020-08-31 US US17/008,108 patent/US11077067B2/en active Active
-
2021
- 2021-07-28 US US17/387,803 patent/US11931464B2/en active Active
- 2021-08-16 IL IL285653A patent/IL285653A/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB2585414B (en) | 2023-06-14 |
US11931464B2 (en) | 2024-03-19 |
WO2020169989A1 (en) | 2020-08-27 |
SG11202108690YA (en) | 2021-09-29 |
IL285653A (en) | 2021-09-30 |
US20200268676A1 (en) | 2020-08-27 |
JP2022521318A (ja) | 2022-04-06 |
BR112021016421A2 (pt) | 2021-10-13 |
US20210353551A1 (en) | 2021-11-18 |
PL3927312T3 (pl) | 2024-02-26 |
TW202045153A (zh) | 2020-12-16 |
EP3927312B1 (en) | 2023-09-13 |
ES2966816T3 (es) | 2024-04-24 |
HUE064472T2 (hu) | 2024-03-28 |
EP4282409A2 (en) | 2023-11-29 |
GB202107172D0 (en) | 2021-06-30 |
US11166919B2 (en) | 2021-11-09 |
EP3927312C0 (en) | 2023-09-13 |
CN113490486A (zh) | 2021-10-08 |
CA3129395A1 (en) | 2020-08-27 |
US11077067B2 (en) | 2021-08-03 |
GB2597577A (en) | 2022-02-02 |
GB2585414A (en) | 2021-01-13 |
GB2597577B (en) | 2023-09-20 |
EP4282409A3 (en) | 2024-02-28 |
KR20210129649A (ko) | 2021-10-28 |
GB202002484D0 (en) | 2020-04-08 |
AU2020223894A1 (en) | 2021-10-14 |
EP3927312A1 (en) | 2021-12-29 |
US20200390716A1 (en) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009679A (es) | Minimizacion de aglomeracion, aireacion y conservacion del revestimiento de composiciones farmaceuticas que comprenden ibuprofeno. | |
ZA202202966B (en) | Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products | |
NZ569012A (en) | Powder compositions for inhalation comprising a force-controlling agent | |
MX351506B (es) | Proceso para fabricar un alimento para mascotas en la forma de una croqueta recubierta. | |
MY153940A (en) | Fertilizer composition containing micronutrients and methods of making same | |
WO2009104187A3 (en) | Bone graft material and uses thereof | |
MX2018016418A (es) | Cloruro compactado de fertilizantes de potasio que contienen nutrientes y metodos para elaborar los mismos. | |
EA201891952A1 (ru) | Композиция удобрений с нанесенным распылением покрытием | |
MX2021013774A (es) | Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares. | |
MX361284B (es) | Particulas de ingrediente activo, recubiertas de goma laca, con propiedades de liberacion controlada, a valores altos de ph, proceso para su fabricacion, y uso de las mismas. | |
AR118159A1 (es) | Minimización de aglomeración, aireación y conservación del revestimiento de composiciones farmacéuticas que comprenden ibuprofeno | |
PH12018500747B1 (en) | Fly ash, cement composition, and method of preparing fly ash | |
MX2022003297A (es) | Proceso para la preparacion de una composicion de mezcla de asfalto. | |
EP4268801A3 (en) | Minimizing aeration of suspensions during in-line mixing | |
MX2020007320A (es) | Proceso para preparar una composicion en polvo. | |
MX2020005876A (es) | Composicion que comprende gliceridos de acidos grasos en polvo. | |
NZ611664A (en) | Plant growth enhancing mixture and method of applying same | |
MY190651A (en) | Highly porous powdered slaked lime composition | |
MX2023001004A (es) | Composiciones farmaceuticas que comprenden un ingrediente farmaceutico activo (api) recubierto. | |
AU8770301A (en) | Process for the preparation of granules of methionine | |
NZ739020A (en) | Thixotropic suspension agent for plant nutrients or animal feed supplements: composition, method of making, and use thereof | |
EA200802335A1 (ru) | Способ получения и поверхностного покрытия гранул | |
MX2021008538A (es) | Sistemas y métodos para elaborar composiciones y productos termoplásticos. | |
CN104530835A (zh) | 一种涂料 | |
ATE376455T1 (de) | Verfahren zur herstellung von beschichteten partikelträgermedien |